3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
3
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Dermatologic
1
Conditions
Leukemia, Myeloid, Acute
4
Myelodysplastic Syndromes
2
Melanoma
2
Uveal Melanoma
1
Recurrence
1
Pancreatic Neoplasms
1
Neoplasm Metastasis
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leukemia
1
Head and Neck Neoplasms
1
Disease Progression
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
pembrolizumab
24
Radiotherapy
21
Cisplatin
21
Cetuximab
13
Carboplatin
11
Paclitaxel
8
Nivolumab
8
durvalumab
7
Radiotherapy, Intensity-Modulated
6
Docetaxel
6
Fluorouracil
5
Cyclophosphamide
5
zalutumumab
4
Everolimus
4
Amifostine
4
spartalizumab
3
fludarabine
3
epacadostat
3
cemiplimab
3
Ipilimumab
3
Immune Checkpoint Inhibitors
3
Gefitinib
3
Filgrastim
3
Erlotinib Hydrochloride
3
Celecoxib
3
Capecitabine
3
selpercatinib
2
palbociclib
2
fludarabine phosphate
2
bintrafusp alfa protein, human
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Head and Neck Neoplasms
×
Valproic Acid
×
Clear all
NCT04729543
2023-12-04
MC2TCR
Erasmus Medical Center
Phase 1/2
Recruiting
20 enrolled